- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
April 28th, 2008
CytImmune Sciences, which is developing a nanotech treatment for cancer, will become the first industry ‘‘customer" to use the biomanufacturing facility at the University of Maryland Biotechnology Institute.
The Rockville facility was built in 2006 specifically to help small companies meet federal quality standards for their products.
CytImmune, with 16 employees, will partner with UMBI's ‘‘good manufacturing practices" facility to help develop AuriTol, which uses nanotechnology to target cancer, said Lawrence Tamarkin, CEO of the Rockville company.
AuriTol is the second drug that CytImmune is developing. The first, Aurimune, will soon enter phase 2 human clinical trials.
|Related News Press|
News and information
Attosecond physics: Mapping electromagnetic waveforms July 25th, 2016
FEI and King Abdullah University of Science and Technology Establish New Electron Microscopy ‘Centre of Excellence’: Centre of Excellence involves materials and life sciences research and technical collaboration July 5th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
New remote-controlled microrobots for medical operations July 23rd, 2016
New probe developed for improved high resolution measurement of brain temperature: Improved accuracy could allow researchers to measure brain temperature in times of trauma when small deviations in temperature can lead to additional brain injury July 23rd, 2016